Provided by Tiger Fintech (Singapore) Pte. Ltd.

Veru Inc.

0.5999
+0.01913.29%
Pre-market: 0.5900-0.0099-1.65%08:50 EDT
Volume:1.83M
Turnover:1.08M
Market Cap:87.94M
PE:-2.42
High:0.6020
Open:0.5800
Low:0.5700
Close:0.5808
Loading ...

Veru Q1 2025 GAAP EPS $(0.06) Beats $(0.07) Estimate, Cash, Cash Equivalents, And Restricted Cash Were $26.6M

Benzinga
·
13 Feb

Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress

GlobeNewswire
·
13 Feb

Veru Inc expected to post a loss of 8 cents a share - Earnings Preview

Reuters
·
11 Feb

Veru to Report Fiscal 2025 First Quarter Financial Results on February 13, 2025

GlobeNewswire
·
06 Feb

Veru Inc expected to post a loss of 8 cents a share - Earnings Preview

Reuters
·
04 Feb

Largest borrow rate increases among liquid names

TIPRANKS
·
30 Jan

Veru Inc.’s Promising Phase IIb Results Suggest Investment Opportunity with Enobosarm’s Weight Management Potential

TIPRANKS
·
28 Jan

S&P 500 Falls Over 100 Points; Dada Nexus Shares Spike Higher

Benzinga
·
28 Jan

Nasdaq Dips 3%; Chicago Fed National Activity Index Rises In December

Benzinga
·
27 Jan

Veru's Enobosarm Meets Primary Endpoint of Preserving Lean Body Mass in Phase 2b Study

MT Newswires Live
·
27 Jan

Veru's experimental drug helps older obese patients on Wegovy preserve muscle

Reuters
·
27 Jan

Veru's muscle preserving drug meets main goal in mid-stage study

Reuters
·
27 Jan

Veru Inc: Study Met Primary Endpoint

THOMSON REUTERS
·
27 Jan

Veru Announces Positive Topline Data From Phase 2B Quality Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving Wegovy® (Semaglutide) for Weight Reduction

THOMSON REUTERS
·
27 Jan

Veru Inc - Enobosarm Treatment Significantly Reduces Lean Mass Loss in Wegovy Patients

THOMSON REUTERS
·
27 Jan

Veru: Patients on Enobosarm on Average Lost 27% More Fat Mass Than Patients Receiving Wegovy Alone

THOMSON REUTERS
·
27 Jan

Veru: Enobosarm Cut Proportion of Patients That Lost Clinically Significant Physical Function VS Those on Wegovy Alone

THOMSON REUTERS
·
27 Jan

Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction

GlobeNewswire
·
27 Jan

What Makes Veru Inc. (VERU) a Strong Momentum Stock: Buy Now?

Zacks
·
24 Jan

Analysts Are Bullish on Top Healthcare Stocks: Argenx Se (ARGX), Veru (VERU)

TIPRANKS
·
12 Jan